The use of recombinant ovine IL-1β and TNF-α as natural adjuvants and their physiological effects in vivo

Immunology and Cell Biology

Volumn 76, Issue 2, 1998, Pages 167-172

  Rothel, J S ^a,c   Seow, H F ^b   Lightowlers, M W ^a   Parry, B W ^a   Gauci, C ^a   Hurst, L ^b   Mucha, M J ^b   Corner, L A ^b   Wood, P R ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSIRO   (Australia)

^c CSL LIMITED   (Australia)

Author keywords

Adjuvant; IL 1 ; TNF ; Vaccination

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; IMMUNOREACTIVITY; SHEEP; VACCINATION; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; AGE FACTORS; ALUMINUM HYDROXIDE; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERLEUKIN-1; MALE; RECOMBINANT PROTEINS; SHEEP; SHEEP DISEASES; TAENIASIS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC;

ANIMALIA; CESTODA; OVIS; OVIS ARIES; TAENIA OVIS;

EID: 0031924849     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1998.00729.x     Document Type: Article

References (28)

1. Cox JC, Coulter AR. Advances in adjuvant technology and application. In: Yong WK (ed.) Animal Parasite Control Utilizing Biotechnology, Boca Raton: CRC Press, 1992: 49-112.
2. Lin R, Tarr PE, Jones TC. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin. Infect. Dis. 1995; 21: 1339-49.
3. East IJ. Adjuvants for new veterinary vaccines. In: Pandey R, Höglund S, Prasad G (eds) Progress in Vaccinology. 4. Veterinary Vaccines. Springer-Verlag, 1993; 1-28.
4. Zimmerman GA, Prescott SM, McIntyre TM. Endothelial cell interactions with granulocytes: Tethering and signalling molecules. Immunol. Today 1992; 13: 93-100.
5. Valle A, Aubry JP, Durand I, Banchereau J. IL-4 and IL-2 upregulate the expression of antigen B7, the B cell counter-structure to T cell CD28: An amplification mechanism for T-B cell interactions. Int. Immunol. 1991; 3: 229-35.
6. Romagnani S. Induction of Th1 and Th2 responses? Immunol. Today. 1992; 13: 379-81.
7. Snapper CM, Mond JJ. Towards a comprehensive view of immunoglobulin class switching. Immunol. Today 1993; 14: 15-17.
8. Heath AW, Playfair JHL. Cytokines as immunological adjuvants. Vaccine 1992; 10: 427-34.
9. Nohria A, Rubin RH. Cytokines as potential vaccine adjuvants. Biotherapy 1994; 7: 261-9.
10. Dong P, Brunn C, Ho RJY. Cytokines as vaccine adjuvants. In: Powell MF, Newman MJ (eds) Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, 1995; 625-43.
11. Heath AW. Cytokines as immunological adjuvants. In: Powell MF, Newman MJ (eds) Vaccine Design: The Subunit and Adjuvant Approach. New York: Plenum Press, 1995; 645-58.
12. Johnson KS, Harrison GBL, Lightowlers MW et al. Vaccination against ovine cysticercosis using a defined recombinant antigen. Nature 1989; 338: 585-7.
13. Seow H-F, Rothel JS, Wood PR. Expression and purification of recombinant ovine interleukin-1β from Escherichia coli. Vet. Immunol. Immunopathol. 1994; 41: 229-39.
14. Seow H-F, Rothel JS, Pepin M, David M-J, Wood PR. Expression, biological activity and kinetics of production of recombinant ovine TNF-α. Vet. Immunol. Immunopathol. 1995; 44: 279-91.
15. Bos ES, van der Doelen AA, van Rooy N, Schuurs AHWM. 3,3′,5,5′ Tetramethylbenzidine as an Ames-test negative chromogen for horse-radish peroxidase in enzyme-immunoassays. J. Immunoassay 1981; 2: 187-204.
16. Nencioni L, Villa L, Tagliabue A et al. In vivo immunostimulating activity of the 163-171 peptide of human IL-1β. J. Immunol. 1987; 139: 800-4.
17. Sloane PJ, Elsasser TH, Spath JA Jr, Albertine KH, Gee MH. Plasma tumor necrosis factor-alpha during long term endotoxemia in awake sheep. J. Appl. Physiol. 1992; 75: 1831-7.
18. Lofthouse SA, Andrews AE, Barcham GJ, Nash AD. Parameters related to the application of recombinant ovine interleukin-1β as an adjuvant. Vaccine 1995; 13: 1277-87.
19. Johnson J, Meyrick B, Jesmok G, Bringham KL. Human recombinant tumor necrosis factor alpha infusion mimics endotoxemia in awake sheep. J. Appl. Physiol. 1989; 66: 1448-54.
20. Vassalli P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 1992; 10: 411-52.
21. Reddy DN, Reddy PG, Minocha HC et al. Adjuvanticity of recombinant bovine interleukin-1β: Influence on immunity, infection, and latency in a bovine herpesvirus-1 infection. Lymphokine Res. 1990; 9: 295-307.
22. Reddy DN, Reddy PG, Xue W, Minocha HC, Daley MJ, Blecha F. Immunopotentiation of bovine respiratory disease virus vaccines by interleukin-1 beta and interleukin-2. Vet. Immunol. Immunopathol. 1993; 37: 25-38.
23. Andrews AE, Lofthouse SA, Bowles VM, Brandon MR, Nash AD. Production and in vivo use of recombinant IL-1β as an immunological adjuvant. Vaccine 1994; 12: 14-22.
24. Nash AD, Lofthouse SA, Barcham GJ et al. Recombinant cytokines as immunological adjuvants. Immunol. Cell Biol. 1993; 71: 367-79.
25. Lofthouse SA, Andrews AE, Nash AD, Bowles VM. Humoral and cellular responses induced by intradermally administered cytokine and conventional adjuvants. Vaccine 1995; 13: 1131-7.
26. Ghiara P, Boraschi D, Nencioni L, Ghezzi P, Tagliabue A. Enhancement of in vivo immune response by tumor necrosis factor. J. Immunol. 1987; 139: 3676-9.
27. Schijns VECJ, Claassen IJMT, Vermeulen AA, Horzinek MC, Osterhaus ADME. Modulation of antiviral immune responses by exogenous cytokines: Effects of tumour necrosis factor-α, interleukin-1β, interleukin-2 and interferon-γ on the immunogenicity of an inactivated rabies vaccine. J. Gen. Virol. 1994; 75: 55-63.
28. Sagara T, Mori S, Ohkawara S, Goto F, Takagi K, Yoshinaga M. A limited role of IL-1 in immune-enhancement by adjuvants. Immunology 1990; 71: 251-7.